Reducing Atrial Pacing Rate to Reduce Atrial Fibrillation in Patients With Sick Sinus Syndrome. (DANPACEII)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02034526 |
Recruitment Status :
Recruiting
First Posted : January 13, 2014
Last Update Posted : January 9, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Atrial fibrillation (AF) is prevalent in patients with sick sinus syndrome (SSS) and associated with an increased risk of stroke and death. Within the first two years after pacemaker implantation almost half of the patients are diagnosed with AF. Studies have indicated that an increased amount of stimulation from the pacemaker in the atria is associated with an increased amount of AF.
The aim of the present study is to test the hypothesis that a reduction of stimulation from the pacemaker in the atria, and reducing the minimal heart rate, increases the time to AF.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sinus Node Disease Atrial Fibrillation | Device: DDDR-60 Device: DDD-40 | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 540 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomised Controlled Trial of Reducing Atrial Pacing Rate to Reduce Atrial Fibrillation in Patients With Sick Sinus Syndrome and Dual Chamber Pacemaker. |
Study Start Date : | May 2014 |
Estimated Primary Completion Date : | January 2022 |
Estimated Study Completion Date : | December 2022 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: DDDR-60
DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
|
Device: DDDR-60
DDDR, lower pacing rate 60 bpm, RR activated (low-moderate) |
Experimental: DDD-40
DDD, lower pacing rate 40 bpm, RR function off
|
Device: DDD-40
DDD, lower pacing rate 40 bpm, RR function off |
- Time to first episode of AF>6 min detected by the pacemaker [ Time Frame: Within two years ]
- Time to first episode of AF>6 hours detected by the pacemaker [ Time Frame: Within two years ]
- Time to first episode of AF>24 hours detected by the pacemaker [ Time Frame: Within two years ]
- Time to direct current (DC) cardioversion or medical cardioversion for AF [ Time Frame: Within two years ]
- Time to stroke, transient ischemic attack (TIA), or thromboembolic event [ Time Frame: Within two years ]
- Time to death [ Time Frame: Within two years ]
- QOL [ Time Frame: After 12 months ]Quality of life assessment with SF-36
- 6MHWT [ Time Frame: After 12 months ]6-minute hall walk test
- Time to need for reprogramming of the pacing rate (cross-over) [ Time Frame: Within 2 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Sick sinus syndrome with and without AV block and indication for first-time implantation of a DDD pacemaker: symptomatic sinus pauses (>2 sec) or bradycardia with or without paroxysmal AF.
- Age ≥18 years.
- Patient informed consent.
Exclusion Criteria:
- Permanent or persisting (>7 days) AF prior to implantation.
- Persisting symptomatic sinus bradycardia and/or chronotropic incompetence where DDD-pacing at a frequency of >40 bpm is indicated (verified with long term ECG monitoring).
- Life expectancy <2 years.
- Participation in another interventional research study.
- Indication for implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT).
- Pregnancy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02034526
Contact: Jens C Nielsen, prof., DMSc. | + 45 78 45 00 00 | jenniels@rm.dk | |
Contact: Mads B Kronborg, MD, PhD | + 45 78 45 00 00 | mads.brix.kronborg@clin.au.dk |
Denmark | |
Department of Cardiology, Aarhus University Hospital | Recruiting |
Aarhus N, Denmark, 8200 | |
Contact: Jens C Nielsen, prof., DMSc. +45 78 45 00 00 jenniels@rm.dk | |
Contact: Mads B Kronborg, MD, PhD. +45 78 45 00 00 mads.brix.kronborg@clin.au.dk | |
Principal Investigator: Jens C Nielsen, prof., DMSc, |
Principal Investigator: | Jens C Nielsen, prof., DMSc, | Department of Cardiology, Aarhus University Hospital |
Responsible Party: | Jens Cosedis Nielsen, Jens Cosedis Nielsen, professor, MD, DMSc, PhD, Aarhus University Hospital |
ClinicalTrials.gov Identifier: | NCT02034526 |
Other Study ID Numbers: |
M-2013-225-13 |
First Posted: | January 13, 2014 Key Record Dates |
Last Update Posted: | January 9, 2020 |
Last Verified: | January 2020 |
Sinus node disease Atrial fibrillation Pacing |
Atrial Fibrillation Sick Sinus Syndrome Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases |
Pathologic Processes Arrhythmia, Sinus Heart Block Cardiac Conduction System Disease |